145 related articles for article (PubMed ID: 38362648)
21. Proton-pump inhibitor therapy and the development of dysplasia in patients with Barrett's oesophagus.
Hillman LC; Chiragakis L; Shadbolt B; Kaye GL; Clarke AC
Med J Aust; 2004 Apr; 180(8):387-91. PubMed ID: 15089728
[TBL] [Abstract][Full Text] [Related]
22. NSAIDs, statins, low-dose aspirin and PPIs, and the risk of oesophageal adenocarcinoma among patients with Barrett's oesophagus: a population-based case-control study.
Masclee GM; Coloma PM; Spaander MC; Kuipers EJ; Sturkenboom MC
BMJ Open; 2015 Jan; 5(1):e006640. PubMed ID: 25633286
[TBL] [Abstract][Full Text] [Related]
23. AGA Clinical Practice Update on New Technology and Innovation for Surveillance and Screening in Barrett's Esophagus: Expert Review.
Muthusamy VR; Wani S; Gyawali CP; Komanduri S;
Clin Gastroenterol Hepatol; 2022 Dec; 20(12):2696-2706.e1. PubMed ID: 35788412
[TBL] [Abstract][Full Text] [Related]
24. Development and Validation of a Model to Determine Risk of Progression of Barrett's Esophagus to Neoplasia.
Parasa S; Vennalaganti S; Gaddam S; Vennalaganti P; Young P; Gupta N; Thota P; Cash B; Mathur S; Sampliner R; Moawad F; Lieberman D; Bansal A; Kennedy KF; Vargo J; Falk G; Spaander M; Bruno M; Sharma P
Gastroenterology; 2018 Apr; 154(5):1282-1289.e2. PubMed ID: 29273452
[TBL] [Abstract][Full Text] [Related]
25. Does the treatment of proton pump inhibitors reduce dysplasia or adenocarcinoma development in Barrett's esophagus?
Akın H; Aydın Y
Turk J Gastroenterol; 2017 Dec; 28(Suppl 1):S31-S32. PubMed ID: 29199164
[TBL] [Abstract][Full Text] [Related]
26. Barrett's esophagus: What do we need to know?
Mohy-Ud-Din N; Krill TS; Shah AR; Chatila AT; Singh S; Bilal M; Parupudi S
Dis Mon; 2020 Jan; 66(1):100850. PubMed ID: 30808502
[TBL] [Abstract][Full Text] [Related]
27. Local Synthesis of Pepsin in Barrett's Esophagus and the Role of Pepsin in Esophageal Adenocarcinoma.
Samuels T; Hoekzema C; Gould J; Goldblatt M; Frelich M; Bosler M; Lee SH; Johnston N
Ann Otol Rhinol Laryngol; 2015 Nov; 124(11):893-902. PubMed ID: 26077392
[TBL] [Abstract][Full Text] [Related]
28. Long-term proton pump induced hypergastrinaemia does induce lineage-specific restitution but not clonal expansion in benign Barrett's oesophagus in vivo.
Obszynska JA; Atherfold PA; Nanji M; Glancy D; Santander S; Graham TA; Otto WR; West K; Harrison RF; Jankowski JA
Gut; 2010 Feb; 59(2):156-63. PubMed ID: 19651631
[TBL] [Abstract][Full Text] [Related]
29. Advances in Barrett's esophagus and esophageal adenocarcinoma.
Shaheen NJ
Gastroenterology; 2005 May; 128(6):1554-66. PubMed ID: 15887151
[TBL] [Abstract][Full Text] [Related]
30. Natural history of Barrett's esophagus.
Milind R; Attwood SE
World J Gastroenterol; 2012 Jul; 18(27):3483-91. PubMed ID: 22826612
[TBL] [Abstract][Full Text] [Related]
31. Lifetime risk of esophageal adenocarcinoma in patients with Barrett's esophagus.
Gatenby P; Caygill C; Wall C; Bhatacharjee S; Ramus J; Watson A; Winslet M
World J Gastroenterol; 2014 Jul; 20(28):9611-7. PubMed ID: 25071359
[TBL] [Abstract][Full Text] [Related]
32. Barrett's esophagus: prevalence and incidence of adenocarcinomas.
Shields HM; Nardone G; Zhao J; Wang W; Xing Z; Fang D; Jacobson BC; Romero Y; Dvorak K; Goldman A; Pellegrini CA; Wiley EL; Peura DA; Tatum RP; Schnell TG
Ann N Y Acad Sci; 2011 Sep; 1232():230-47. PubMed ID: 21950816
[TBL] [Abstract][Full Text] [Related]
33. Barrett's esophagus.
Falk GW
Gastrointest Endosc Clin N Am; 1994 Oct; 4(4):773-89. PubMed ID: 7812646
[TBL] [Abstract][Full Text] [Related]
34. Proton pump inhibitors reduce the risk of neoplastic progression in patients with Barrett's esophagus.
Kastelein F; Spaander MC; Steyerberg EW; Biermann K; Valkhoff VE; Kuipers EJ; Bruno MJ;
Clin Gastroenterol Hepatol; 2013 Apr; 11(4):382-8. PubMed ID: 23200977
[TBL] [Abstract][Full Text] [Related]
35. Do proton pump inhibitors prevent Barrett's esophagus progression to high-grade dysplasia and esophageal adenocarcinoma? An updated meta-analysis.
Chen Y; Sun C; Wu Y; Chen X; Kailas S; Karadsheh Z; Li G; Guo Z; Yang H; Hu L; Zhou Q
J Cancer Res Clin Oncol; 2021 Sep; 147(9):2681-2691. PubMed ID: 33575855
[TBL] [Abstract][Full Text] [Related]
36. Prospective evaluation of the prevalence of gastric Helicobacter pylori infection in patients with GERD, Barrett's esophagus, Barrett's dysplasia, and Barrett's adenocarcinoma.
Weston AP; Badr AS; Topalovski M; Cherian R; Dixon A; Hassanein RS
Am J Gastroenterol; 2000 Feb; 95(2):387-94. PubMed ID: 10685740
[TBL] [Abstract][Full Text] [Related]
37. Helicobacter pylori eradication treatment and the risk of Barrett's esophagus and esophageal adenocarcinoma.
Doorakkers E; Lagergren J; Santoni G; Engstrand L; Brusselaers N
Helicobacter; 2020 Jun; 25(3):e12688. PubMed ID: 32175626
[TBL] [Abstract][Full Text] [Related]
38. Esophageal adenocarcinoma in a first-degree relative increases risk for esophageal adenocarcinoma in patients with Barrett's esophagus.
Tofani CJ; Gandhi K; Spataro J; Yoo J; Murphy M; Mohan N; Daitch Z; Shah A; Janowski R; Huntley C; Dabbish N; Keith S; Coben R; Cohen S; Kastenberg D; Infantolino A
United European Gastroenterol J; 2019 Mar; 7(2):225-229. PubMed ID: 31080607
[TBL] [Abstract][Full Text] [Related]
39. Quality indicators for the management of Barrett's esophagus, dysplasia, and esophageal adenocarcinoma: international consensus recommendations from the American Gastroenterological Association Symposium.
Sharma P; Katzka DA; Gupta N; Ajani J; Buttar N; Chak A; Corley D; El-Serag H; Falk GW; Fitzgerald R; Goldblum J; Gress F; Ilson DH; Inadomi JM; Kuipers EJ; Lynch JP; McKeon F; Metz D; Pasricha PJ; Pech O; Peek R; Peters JH; Repici A; Seewald S; Shaheen NJ; Souza RF; Spechler SJ; Vennalaganti P; Wang K
Gastroenterology; 2015 Nov; 149(6):1599-606. PubMed ID: 26296479
[TBL] [Abstract][Full Text] [Related]
40. Lack of incremental effect of histamine receptor antagonists over proton pump inhibitors on the risk of neoplastic progression in patients with Barrett's esophagus: a cohort study.
Thota PN; Hajifathalian K; Benjamin T; Runkana A; Lopez R; Sanaka MR
J Dig Dis; 2017 Mar; 18(3):143-150. PubMed ID: 28188977
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
